![]() ![]() The vial stoppers are not made with natural rubber latex. One vial contains lyophilized recombinant respiratory syncytial virus glycoprotein F stabilized in pre-fusion conformation (RSVPreF3) as the antigen component, which must be reconstituted at the time of use with the accompanying vial of GSK’s proprietary AS01E adjuvant as the adjuvant suspension component. What are the ingredients in Arexvy?Īrexvy is an adjuvanted respiratory syncytial virus vaccine that is supplied in two vials that must be reconstituted before administration. Discard reconstituted vaccine that has not been used within 4 hours. StorageĪrexvy should be administered immediately after reconstitution or stored protected from light for up to 4 hours in the refrigerator between 2☌ and 8☌ (36☏ to 46☏) or at room temperature. How is Arexvy administered?Īrexvy is given by intramuscular injection, usually into the deltoid muscle of the upper arm.ĭetailed Arexvy dosage information What are the side effects of Arexvy?Īrexvy is generally well tolerated and the most common side effects included injection site pain, fatigue, mild to moderate muscle or joint aches, or headache. ChildrenĪrexvy is not approved for children. Other adults, pregnancy, or lactationĪrexvy is not approved for use in persons <60 years of age. People who are immunocompromised, including those receiving immunosuppressive therapy, may have a diminished immune response to Arexvy. ![]() Procedures should be in place to avoid injury from fainting. Syncope (fainting)įainting may occur following the administration of vaccines. Warnings Possible anaphylactic reactionsĪrexvy should be administered in a facility that can provide the appropriate medical treatment and supervision to manage possible anaphylactic reactions following administration. ![]() Who should not receive Arexvy?ĭo not administer Arexvy to anyone with a known hypersensitivity to Arexvy or any of its components. The vaccine showed 94.6% efficacy in reducing the risk of developing RSV-associated LRTD in older adults with underlying conditions, with an overall efficacy of 82.6%.Īrexvy was approved on May 3, 2023, and it was the first RSV vaccine to be approved for older adults. The dynamic transitions and kinetic movements help introduce one app feature and then move on to the next. RSV is a common, contagious virus that can cause hospitalization and death, especially in older adults with underlying medical conditions such as diabetes and chronic heart and lung diseases. At the core of this After Effects app promo video template is a floating mobile phone on a sea of warm, attention-grabbing colors. It works by inducing an immune response against the RSVpreF3 antigen which will protect older adults against LRTD caused by RSV. Last updated on May 23, 2023.Īrexvy is a respiratory syncytial virus (RSV) vaccine that may be used to immunize people aged 60 years and older against lower respiratory tract disease (LRTD) caused by RSV. Medically reviewed by Carmen Pope, BPharm. Generic name: respiratory syncytial virus vaccine, adjuvantedĭosage form: suspension for intramuscular injection ![]()
0 Comments
Leave a Reply. |